profit from every $100 of sales.
$0$100
Scinai Immunotherapeutics
$0.40-9.50% today
-96.0% in 1 year
1-year low $0.401-year high $12.40
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Scinai Immunotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $1.31 million in 2025, with -$8.31 million of profit last year.
SalesProfit
Scinai Immunotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Scinai Immunotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Scinai Immunotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 1 | 1 | |
| 0 | 0 | -1 | -3 | |
| -11 | -10 | -9 | -8 | |
| -5 | -2 | 8 | -7 | |
| -6 | -7 | 5 | -8 | |
| -40.00 | -16.00 | 0.00 | – | |
| – | – | -88.1% | -202.3% | |
| – | – | -1,312.8% | -575.3% | |
| – | – | 728.9% | -633.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 27 | 17 | 13 | 12 |
| Cash | 14 | 5 | 2 | 2 |
| Total debt | 22 | 21 | 2 | 2 |
| Total liabilities | 29 | 22 | 3 | 4 |
| -2 | -5 | 10 | 8 | |
| 0 | 0 | 1 | – | |
| -23.1% | -13.3% | 40.7% | -60.5% | |
| 329.3% | 142.3% | 48.1% | -102.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7 | -9 | -6 | -6 | |
| 1 | 1 | 0 | 0 | |
| -8 | -10 | -6 | -6 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 0.1×
- 0.8×
- –
- –
- -575.5%
- -789.5%
- 0.0%
Profitability
- -202.3%
- -575.3%
- -633.6%
- -496.8%
- -72.7%
- -27.5%
- -98.3%
- -71.5%
- -75.1%
- 180.3%
Growth
- +99.2%
- –
- +4.6%
- –
- +118.4%
Financial health
- –
- 0.28
- 19.5%
- -21.0×
- 1.30
- 1.30
- 0.11
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 2%of 963
Top 5%of 908
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Dec 2, 2025 | -1.33 | – | – |
| Sep 2, 2025 | -3.57 | – | – |
| May 30, 2025 | -0.00 | – | – |
| May 7, 2025 | -10.40 | – | – |
| Nov 22, 2024 | 8.40 | – | – |
| Aug 15, 2024 | -3.57 | – | – |
| Jul 2, 2024 | -4.00 | – | – |
| May 15, 2024 | -240.00 | -0.62 | −38,609.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/6Passes 2 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
62Pass
Philip Fisher
39No pass
Peter Lynch
96Pass
Joel Greenblatt
–Not enough data
Charlie Munger
36No pass
Terry Smith
35No pass
Questions about Scinai Immunotherapeutics
Is Scinai Immunotherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Scinai Immunotherapeutics AI analysis
What does Scinai Immunotherapeutics do?
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It is in Biotechnology.
Does Scinai Immunotherapeutics pay a dividend?
No. Scinai Immunotherapeutics does not pay a dividend at the moment.
Is Scinai Immunotherapeutics stock halal?
No. Scinai Immunotherapeutics does not pass our halal screen: its debt is 215% of its market value, at or above the 33% limit. How we check
How has Scinai Immunotherapeutics stock done over the past year?
Down 96.0% over the past twelve months, to $0.40. It traded between $0.40 and $12.40 and is 96.8% below its high.
Who are Scinai Immunotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Scinai Immunotherapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.